Diagnostic Delay, Comorbid Hidradenitis Suppurativa and the Prognostic Value of Bacterial Culture in Folliculitis Decalvans: A Cohort Study

Adalimumab improved folliculitis decalvans in most patients.

Tofacitinib may effectively treat folliculitis decalvans.

In this multicenter study, androgenetic alopecia was the most common type of alopecia among both men and women attending specialty hair clinics on four continents.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

This study examined the therapeutic response to folliculitis decalvans treatments among 60 patients and found that earlier disease onset was linked to more severe cases, while a combination of rifampicin, clindamycin, tetracyclines, and intralesional steroids was most effective in controlling symptoms.

In this retrospective study, oral isotretinoin monotherapy effectively achieved remission in 82% of patients with folliculitis decalvans, with those receiving ≥0.4 mg/kg/day for ≥3 months experiencing better outcomes and less frequent relapse.

This article reviews various types of primary cicatricial alopecias and emphasizes the importance of accurate diagnosis to improve management strategies, particularly detailing remaining lymphocytic forms and expanding on neutrophilic and mixed types.

This study found that discoid lupus erythematous was the most common type of primary cicatricial alopecia, predominantly affecting middle-aged women.

This study found that among patients with folliculitis decalvans, treatment with isotretinoin achieved the highest rate of stable remission compared to antibiotic regimens like clindamycin and rifampicin.

This study found that severe folliculitis decalvans was associated with its onset before age 25 and the presence of pustules, while tetracyclines and clindamycin plus rifampicin were effective treatments.

This study found that most patients with folliculitis decalvans showed improvement and remission with oral antibiotics, although some experienced relapses and required prolonged treatment.

This case series reports 13 patients with folliculitis decalvans treated with antimicrobial therapy, highlighting the variability in response outcomes for this challenging condition.

This review outlines the diagnosis and management of folliculitis decalvans, an inflammatory scalp disorder, and highlights Staphylococcus aureus and immune response deficiencies as key factors in its development.

This review examines the clinical features, histology, and treatment options for various neutrophilic and mixed primary cicatricial alopecias, but presents no new data.

This study reviewed the epidemiology and treatment of inflammatory cicatricial alopecias and highlighted the importance of scalp biopsies for accurate diagnosis in a mixed ethnic population at a university hair clinic.

This study reported that a treatment regimen of oral rifampicin and clindamycin for 10 weeks effectively managed folliculitis decalvans, with most patients experiencing no recurrence after one or multiple courses.